The Real Life Topical Field Treatment of Actinic Keratosis Study

Actinic Keratosis Clinical Trial

— RAPID-ACT  

Official title:

The Real Life Topical Field Treatment of Actinic Keratosis Study. An Observational Study Focusing on Patient Reported Outcomes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02362152
• Other study ID #: NIS-PICATO-1116
• Status: Completed
• Start date: July 2014
• Est. completion date: December 2015

Study information

• Verified date: December 2019
• Source: LEO Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This non-interventional, multinational study of topical field treatment of actinic keratosis (AK) aims to collect real-life experience with ingenol mebutate as well as one or two other topical field therapies commonly used in the individual country. Physicians will report baseline characteristics, while the main study focus will be on patient reported outcomes 3-4 weeks after treatment completion (treatment satisfaction, adherence, resource utilization and Health Related Quality of Life.

Dermatology centres in Denmark, Norway, Sweden, the Netherlands, the United Kingdom and Canada will participate.

Description:

Actinic keratosis (AK) is caused by exposure to UV radiation and has the potential to regress to normal skin or to squamous cell carcinoma. AK treatment options include cryotherapy for solitary lesions and topical field therapy or photodynamic therapy for lesions in an area of sun-damaged skin. This prospective, non-interventional, multinational study aims to describe and compare in a real-life setting the treatment satisfaction, treatment adherence, resource utilization and quality of life during topical field treatment of AK with 5-fluorouracil, imiquimod, diclofenac and ingenol mebutate.

Dermatology centres in Denmark, Sweden, Norway, Canada, the United Kingdom and the Netherlands will aim to include a total of approximately 1600 patients, of which around 100 in each country will be patients scheduled to receive treatment with ingenol mebutate. In each country patients will in addition be recruited for one or two of the other treatment arms, as appropriate in the country.

Only adult patients scheduled to start treatment with imiquimod, 5-fluorouracil, diclofenac or ingenol mebutate who have given informed consent to use data from their medical records for the study and to report study data themselves will be included and followed for the duration of the scheduled treatment + 3-4 weeks.

Physician will report patient demographics and AK characteristics at baseline. Patients will at baseline report AK Quality of Life, including general attitude regarding sun damaged skin at baseline, and, if applicable, treatment satisfaction and adherence with latest previous AK treatment. At 3-4 weeks after end of treatment, the patients will report treatment satisfaction, adherence, resource utilization, health related Quality of Life.

Treating physicians report drug-related Adverse Events in accordance with national laws and regulations and normal clinical practice.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1168
• Est. completion date: December 2015
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria: Patients eligible to receive topical treatment with one of the following for treatment of actinic keratosis at the discretion of the dermatologist: Ingenol mebutate, 5-fluorouracil, imiquimod, diclofenac. Informed consent.

-

Exclusion Criteria: Any on-going treatments at study start with ingenol mebutate, 5-fluorouracil, imiquimod or diclofenac; other topical treatment for AK in treatment area; pregnancy or planned pregnancy within treatment period.

-

Related Conditions & MeSH terms

• Actinic Keratosis
• Keratosis
• Keratosis, Actinic

Intervention

Drug:
• Ingenol mebutate
Topical field treatment as prescribed by dermatologist
• 5-fluorouracil
Topical field treatment as prescribed by dermatologist
• Imiquimod
Topical field treatment as prescribed by dermatologist
• Diclofenac
Topical field treatment as prescribed by dermatologist

Locations

Country	Name	City	State
Netherlands	Lievensberg Ziekenhuis	Bergen op Zoom

Sponsors (1)

Lead Sponsor	Collaborator
LEO Pharma

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment satisfaction	Treatment Satisfaction Questionnaire of Medication TSQM 9	3-4 weeks after end of treatment
Secondary	Adherence	Morisky Medication Adherence Scale	3-4 weeks after end of treatment
Secondary	Health Related Quality of Life EQ-5D-5L	General measure of health outcome	Baseline and 3-4 weeks after end of treatment
Secondary	DLQI	Dermatology Life Quality Index	Baseline and 3-4 weeks after end of treatment
Secondary	WPAI	Work Productivity and Activity Impairment Questionnaire	3-4 weeks after end of treatment
Secondary	Local Skin Response	Occurrence and duration of redness of skin, dry skin, burning, or stinging	Up to 3-4 weeks after end of treatment